(12Z)-4,7-dimethyl-6-oxa-3,7-diazabicyclo[12.3.1]octadeca-1(17),12,14(18),15-tetraene-2,8-dione

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: (12Z)-4,7-dimethyl-6-oxa-3,7-diazabicyclo[12.3.1]octadeca-1(17),12,14(18),15-tetraene-2,8-dione
• 化学式: C₁₇H₂₂N₂O₃
• 分子量: 302.37
• InChiKey: BSELCZBBNJDIOO-DAXSKMNVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• CRYSTALLINE FORM OF VSN16
  申请人：UCL Business PLC

  公开号：EP2945619B1

  公开（公告）日：2019-05-08
• [EN] CRYSTALLINE FORM OF VSN16<br/>[FR] FORME CRISTALLINE DE VSN16
  申请人：CANBEX THERAPEUTICS LTD

  公开号：WO2014111720A1

  公开（公告）日：2014-07-24

  The present invention relates to a compound of formula (I) in crystalline form, wherein said compound is in the form of the free base or a pharmaceutically acceptable salt thereof, or a solvate of the free base or salt form thereof.The invention also relates to a pharmaceutical composition containing said crystalline form as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process for preparing the crystalline form.